Oxybutynin Transdermal Patch
Urinary Bladder Disorder
University of California, DavisUNKNOWNPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Urinary Bladder Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tamsulosin Centre Hospitalier Universitaire de Nīmes | Phase 3 | BB |
Cranberry Rennes University Hospital | Phase 3 | B |
Oxybutynin University of California, Davis | Phase 3 | B |
Alfuzosin Nova Scotia Health Authority | Phase 2/3 | CCC |
Tranexamic Acid Fraser Health | Phase 1/2 | CCC |
View all 10 →
Same molecule, other indications
Oxybutynin Transdermal Patch is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →